Onconetix, Inc. Files 8-K: Standard Disclosure
Ticker: ONCO · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1782107
Sentiment: neutral
Topics: disclosure, filing, sec
TL;DR
Onconetix (ONCO) filed a standard 8-K, no major news.
AI Summary
Onconetix, Inc. filed an 8-K on March 24, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio. This filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine update for investors, confirming the company's ongoing compliance and reporting requirements with the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with no new material information, indicating no immediate change in risk.
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former company name
- Blue Water Vaccines Inc. (company) — Former company name
- March 24, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Onconetix, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to include Financial Statements and Exhibits as of March 24, 2025.
What were the previous names of Onconetix, Inc.?
Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. (name change effective April 24, 2023) and Blue Water Vaccines Inc. (name change effective July 10, 2019).
Where is Onconetix, Inc. incorporated and what is its principal executive office address?
Onconetix, Inc. is incorporated in Delaware and its principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.
What is the SIC code for Onconetix, Inc.?
The Standard Industrial Classification (SIC) code for Onconetix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this 8-K filing disclose any specific new financial results or material events?
This 8-K filing primarily serves as a current report for Regulation FD Disclosure and Financial Statements and Exhibits, and does not appear to disclose specific new financial results or material events beyond these standard reporting categories.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Onconetix, Inc. (ONCO).